scispace - formally typeset
S

Sonja Hartwig

Researcher at University of Düsseldorf

Publications -  81
Citations -  2850

Sonja Hartwig is an academic researcher from University of Düsseldorf. The author has contributed to research in topics: Adipose tissue & Medicine. The author has an hindex of 23, co-authored 70 publications receiving 2366 citations.

Papers
More filters
Journal ArticleDOI

Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome

TL;DR: DPP4 is a novel adipokine that may impair insulin sensitivity in an autocrine and paracrine fashion and release strongly correlates with adipocyte size, potentially representing an important source of DPP4 in obesity.
Journal ArticleDOI

Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders.

TL;DR: Although the entirety of human adipokines is still incompletely characterized, to date more than 600 potentially secretory proteins were identified providing a rich source to identify putative novel biomarkers associated with metabolic diseases.
Journal ArticleDOI

Identification and Validation of Novel Adipokines Released from Primary Human Adipocytes

TL;DR: Validation experiments conducted for complement factor H, αB-crystallin, cartilage intermediate-layer protein, and heme oxygenase-1 show that the release and expression of these factors in adipocytes is regulated by differentiation and stimuli, which affect insulin sensitivity, as well as by obesity.
Journal ArticleDOI

Pigment epithelium-derived factor (PEDF) is one of the most abundant proteins secreted by human adipocytes and induces insulin resistance and inflammatory signaling in muscle and fat cells.

TL;DR: PEDF is one of the most abundant adipokines and its secretion is inversely regulated by insulin and hypoxia, which could have an important role in diabetes and obesity-related disorders.
Journal ArticleDOI

Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass

TL;DR: The alb-SREBP-1c mouse model allowed the elucidation of the systemic impact of SREBP -1c as a central regulator of lipid metabolism in vivo and also demonstrated that the liver is a more active player in metabolic diseases such as visceral obesity and insulin resistance.